AstraZeneca is weighing cancer-vaccine development as Merck and Moderna reported a 42% lower chance of relapse or death in Phase 3 melanoma testing. The U.K. drugmaker's interest has appeared in numerous internal discussions, CEO Pascal Soriot said in remarks to analysts at the European Society for Medical Oncology conference in Madrid.

CEO Pascal Soriot said: "Our R&D team has done a lot of work in the last couple of years on mRNA technology." Bloomberg reported that the comments followed repeated internal discussions about cancer vaccines. He added that AstraZeneca believed it could achieve something in the field and would provide further information in the coming months and years.

What is AstraZeneca considering?

The comments provide the clearest indication yet that AstraZeneca has an appetite for cancer vaccines, Bloomberg said. Although the company previously partnered with Oxford University on a COVID-19 vaccine, it has mostly concentrated on cancer, cardiometabolic (cardiovascular and metabolic) and rare-disease drugs.

Any expansion would represent a portfolio extension beyond the three drug areas on which AstraZeneca has concentrated. Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, set the strategic filter.

Fredrickson said: "We have to play in the spaces where we can win, and winning is about being best in class, being first, leveraging scale." He made the comments in a Saturday interview.

Where does AstraZeneca face the bigger gap?

Fredrickson said other companies are better positioned to advance personalized cancer vaccines. He said AstraZeneca's infectious-disease unit has an interest in non-personalized vaccines, although proof for that approach remains more limited at this stage.

Personalized cancer vaccines use an individual patient's tumor as their basis. Non-personalized vaccines would target larger groups of people whose cancers are alike. The models create distinct tests: leadership against better-positioned personalized developers, or participation in a broader approach with less evidence.

What did the Phase 3 results show?

Merck and Moderna reported detailed Phase 3 (late-stage clinical trial) results for their personalized mRNA therapy used with Merck's Keytruda. In patients with completely resected stage IIB-IV melanoma, the combination lowered the chance of relapse or death by 42% compared with Keytruda alone.

The companies are also running nine Phase 2 (mid-stage clinical trial) and Phase 3 trials across tumor types. The nine-trial scope provides the immediate benchmark for AstraZeneca's prospective entry and supports Fredrickson's assessment that competitors hold the stronger position in personalized vaccines.

Can personalized vaccines scale?

Susan Galbraith, executive vice president of oncology hematology R&D, said she wanted additional evidence on how well personalized vaccines perform across more types of cancer. The conference presented data showing effectiveness in melanoma, but her request extends the evidence requirement beyond that tumor type.

Galbraith also identified cost and turnaround time as production constraints. She said those factors would still make it challenging to scale the treatment to the vast numbers of patients, shifting the commercial test from efficacy alone to production reach.

What does the six-week production cycle mean?

Merck CEO Rob Davis expects the personalized vaccine to become faster to manufacture over time. The journey from tumor sequencing (genomic analysis of a patient's tumor) to delivery of the finished vaccine at a hospital takes six weeks. Davis's forecast makes process improvement a competitive variable alongside clinical performance and trial breadth.

What is the strategic decision?

AstraZeneca has moved cancer vaccines into active internal consideration, but the Madrid remarks set direction rather than a launch schedule. Soriot promised more information in the months and years ahead, while Fredrickson tied participation to areas where the company can lead.

The evidence base remains uneven: personalized vaccines have shown effectiveness in melanoma, but Galbraith wants broader cancer data. Non-personalized vaccines offer a larger-group model, though their proof remains limited. Manufacturing adds a third constraint, with a six-week cycle that Davis expects to shorten.

AstraZeneca's case therefore rests on three conditions: leadership in a chosen field, evidence across more tumors and production capable of serving a large patient population. Soriot's reference to information in the months and years ahead leaves the development timetable open while clinical breadth and manufacturing constraints remain unresolved.